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Sentinel Lymph Node Biopsy Pathology 
and 2-Year Postsurgical Recurrence of 
Breast Cancer in Kenyan Women
INTRODUCTION
Breast cancer is the most common malignan-
cy among women worldwide, causing 522,000 
deaths in 2012.1 Although the per capita inci-
dence of this disease is greater in more devel-
oped countries, patient fatality rates are sig-
nificantly higher in low- and middle-income 
countries.1 This has led to a significant global 
effort to promote early diagnosis and treatment 
of breast cancer in low-resource settings.2,3 Cur-
rently, most patients with breast cancer in low- 
and middle-income countries are diagnosed at 
an advanced stage; however, the promotion of 
early diagnosis and treatment is expected to lead 
to an increase in stage I and II diagnoses,4 which 
are associated with significantly better outcomes 
than are stage III or IV disease.
In Kenya, breast cancer is the most common ma-
lignant neoplasm in women, with an age-stan-
dardized incidence rate of 51.7 per 100,000 
women.5 Although no long-term follow-up data 
on 5-year survival are available from Kenya, in 
Uganda, the reported cumulative 5-year surviv-
al is 51.8%.6 At Aga Khan University Hospital 
(AKUH), a 300-bed teaching hospital in Nai-
robi, Kenya, patients with stage I and II breast 
cancer are offered a sentinel lymph node biopsy 
(SLNB). The importance of this procedure in the 
management of early-stage breast cancer con-
tinues to be affirmed in guidelines from high-in-
come countries (HICs),7 and knowledge of its 
importance is growing in low-resource settings 
as well, as demonstrated by the recent Interna-
tional Atomic Energy Agency’s meeting on set-
ting up SLNB programs in developing countries.8 
Purpose The goal of this study was to describe the pathologic findings and early follow-up expe-
rience of patients who underwent a sentinel lymph node biopsy (SLNB) at Aga Khan University 
Hospital (AKUH) between 2008 and 2017.
Patients and Methods We performed a retrospective analysis of women with breast cancer who 
underwent an SLNB at AKUH between 2008 and 2017. The SLNB was performed on patients with 
stage I and stage II breast cancer, and identification of the sentinel lymph node was made by 
radioactive tracer, blue dye, or both, per availability and surgeon preference. Demographic, sur-
gical, and pathologic data, including immunohistochemistry of the surgical sample for estrogen 
receptor, progesterone receptor, and human epidermal growth factor receptor 2, were abstracted 
from the patient records. Follow-up data were available for a subset of patients.
Results Between 2008 and 2017, six surgeons performed SLNBs on 138 women, 129 of whom had 
complete records and were included in the study. Thirty-one of 129 (24%) had a positive SLNB, 
including 10 of 73 (14%) with stage I and 21 of 56 (38%) with stage II disease. Seventy-eight 
patients (60%) received systemic adjuvant chemotherapy and 79 (62%) received radiation ther-
apy, and of the 102 patients who were estrogen receptor positive, 86 (85%) received endocrine 
therapy. Seventy-nine patients were observed for > 2 years, and, of these, four (5.1%) had a 
regional recurrence.
Conclusion The SLNB positivity rates were similar to those of high-income country (HIC) cohorts. 
However, preliminary data suggest that recurrence rates are elevated at AKUH as compared with 
those of HIC cohorts, perhaps because of a lower use of radiotherapy and chemotherapy at AKUH 
compared with HIC cohorts or because of differences in the characteristics of the primary tumor 
in patients at AKUH as compared with those in HICs.
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However, despite this support, many barriers to 
creating SLNB programs in low-resource set-
tings, including lack of specialist training, limited 
resources, and equipment shortages, have been 
identified.9 In addition, limited data have been 
published on successful SLNB programs in Afri-
ca, and no data have been published from East 
Africa. In this retrospective study, we describe 
the pathologic findings of patients who under-
went an SLNB at AKUH between 2008 and 
2017 together with their experience with breast 
cancer recurrence in the subsequent 2 years.
PATIENTS AND METHODS
Hospital Site
AKUH is a not-for-profit teaching hospital in Nai-
robi with 300 beds and an average of 170 new 
breast cancer diagnoses per year. The hospital 
has a dedicated breast clinic and is able to of-
fer multidisciplinary care that includes nuclear 
medicine, surgery, chemotherapy, radiotherapy, 
and pathology services, which are all coordinat-
ed through weekly breast tumor boards.
Ethical Approval
The AKUH’s institutional review board approved 
this retrospective study, and a de-identified data 
set was created by an AKUH research nurse for 
the data analysis. Columbia University provided 
an institutional review board exemption because 
their personnel worked with the de-identified 
data only.
Data Abstraction
Cross-referencing patient records from the sur-
gical, nuclear medicine, and pathology depart-
ments identified patients who underwent an 
SLNB. AKUH study personnel abstracted data 
into an Excel spreadsheet (Microsoft, Seattle, 
WA) on all women who underwent an SLNB be-
tween 2008 and 2017 for clinical stage I or II 
malignant breast cancer.
Surgeons
Six general surgeons at AKUH performed SLNBs 
during the study period. Of the six, two surgeons 
completed > 95% of the caseload. These two 
surgeons were both trained outside of Kenya on 
SLNB technique: one surgeon received training 
through a breast fellowship in Canada, and the 
other completed a surgical oncology fellowship in 
India. Another surgeon, who completed a breast 
fellowship in South Africa in 2016 and only re-
cently returned to AKUH, contributed three cas-
es, and three other AKUH surgeons each con-
tributed a single SLNB case to the study.
SLNB Procedure
The six AKUH surgeons performed the SLNB 
procedure on stage I and stage II patients with 
no nodal or metastatic disease. Nodal status 
was determined by physical examination, and 
metastatic work-up included chest and ab-
dominal computed tomography and bone scan 
on all patients. The sentinel lymph node (SLN) 
was identified using lymphoscintigraphy with 
99mTc-nanocolloid and gamma probe or lymphat-
ic dye mapping with methylene blue, or both, 
depending on surgeon preference and consum-
able availability. Identified SLNs were removed 
from the patient and were analyzed by a pathol-
ogist using touch prep, scrape prep, fresh-fro-
zen sectioning, or a combination of approaches, 
depending on pathologist preference.
Pathology
Postoperatively, all samples were delivered to the 
pathology laboratory for permanent fixation and 
processing. Hematoxylin and eosin–stained sec-
tions of the SLNs and the primary tumor were 
examined for tumor type, and histopathologic 
features of prognostic significance such as tumor 
grade and lymphovascular invasion were noted.
Immunohistochemistry
Details of the immunohistochemistry (IHC) pro-
cedures at AKUH have been described previ-
ously.10 In brief, tumor sections were stained for 
estrogen receptor (ER; FLEX RTU monoclonal 
rabbit anti-human ER α, clone EP1), progester-
one receptor (PR; FLEX RTU monoclonal rab-
bit anti-human PgR 636 antibody clone), and 
human epidermal growth factor receptor 2 (HER2)/
neu (polyclonal rabbit anti-human c-erbB-2 
oncoprotein diluted 1:200 with the EnVisio FLEX 
antibody diluent) on the Dako Autostainer Link 48 
platforms, using EnVisio FLEX Kit detection kits 
(Dako, Santa Clara, CA). Interpretation for ER/
PR used the Allred scoring system,11 and HER2 
positivity was scored using the ASCO/College of 
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American Pathologists scoring system,12 with 
equivocal samples receiving fluorescent in situ 
hybridization to assess gene amplification.
Data Analysis
Data were exported to and analyzed in Stata SE 
12 (StataCorp, College Station, TX). Categorical 
variables were analyzed using the χ2 test, and 
continuous variables were assessed using the 
Wilcoxon rank sum test or the t test, depending 
on the normality of the distribution of the variable.
RESULTS
Between July 1, 2008, and April 30, 2017, 138 
women underwent an SLNB by one of the six 
study surgeons. Nine of these patients, however, 
had undergone an SLNB before AKUH’s transi-
tion to an electronic medical record system and 
therefore were excluded from our study due to 
significant missing data. This left a final sample 
of 129 patients, including 73 with stage I and 56 
with stage II disease. At least one SLN was found 
in 100% of these patients. A positive SLNB was 
found in 31 (24%) of the patients, including 10 
of 73 (14%) with stage I and 21 of 56 (38%) with 
stage II disease. Of the 31 patients with a posi-
tive SLNB, 23 proceeded to axillary lymph node 
dissection (ALND) and eight were treated with 
an SLNB alone after a change in ASCO’s practice 
guidelines.13 Of the 23 patients with a positive 
SLNB who underwent an ALND, 21 (91%) were 
found to have one or more other positive nodes. 
Tables 1 and 2 list the demographic, surgical, 
and pathologic characteristics associated with 
SLN positivity and demonstrate the association 
between younger age, stage II disease, lympho-
vascular invasion, and histologic diagnosis and 
SLN positivity. Of the 129 patients, 78 (60%) 
received systemic adjuvant chemotherapy, 79 
(62%) received radiation therapy, and 86 (85%) 
of the 102 patients with ER positivity received 
endocrine therapy. During the study period, 
three patients with a negative SLNB underwent 
an ALND for unknown reasons. None of these 
patients had a positive node on ALND (Fig 1).
Of the 129 patients included in our study, 126 
underwent IHC for ER, PR, and HER2 receptors. 
Rates of ER+, PR+, HER2+, and triple-nega-
tive disease were 81%, 78%, 13%, and 15%, 
respectively. A subset analysis among the 65 
black patients showed similar results, with ER+, 
PR+, HER2+, and triple-negative disease rates 
of 80%, 77%, 17%, and 14%.
Seventy-nine patients were observed for at least 
2 years after surgery. Of these, two (3.2%) of the 
62 patients with a negative SLNB and two (12%) 
of the 17 patients with a positive SLNB had a re-
gional recurrence within 2 years, giving an over-
all 2-year regional recurrence rate of 5.1%. Ta-
ble 3 lists the clinical characteristics of the four 
patients who had a regional recurrence. All four 
of these patients received both adjuvant chemo-
therapy and radiation therapy for the treatment 
of their initial breast cancer.
DISCUSSION
The SLNB procedure has been shown to be the 
standard of care for the management of ear-
ly-stage breast cancer, with many trials showing 
that the procedure leads to less morbidity than 
ALND and results in no difference in overall 
survival.14-17 Despite the widespread adoption 
3  jgo.org JGO – Journal of Global Oncology
Table 1. Demographic and Surgical Characteristics by Sentinel Lymph Node Positivity
Characteristic
Negative SLNB 
(n = 98)
Positive SLNB 
(n = 31) P*
Demographics
 Age, years, mean (range) 58 (34-88) 51 (31-86) .02
 Ethnicity, No. (%) .80
  Black 53 (54) 15 (48)
  White 17 (17) 7 (23)
  Other 28 (29) 9 (29)
Surgery
 Clinical stage, No. (%) .002
  Stage I 63 (64) 10 (32)
  Stage II 35 (36) 21 (68)
 No. of SLNs, median (range) 2 (1-6) 2 (1-6) .50
 Underwent ALND, No. (%) 3 (3.1) 23 (74) < .001
 Dye used, No. (%) .40
  Methylene blue dye 16 (16) 2 (6.5)
  99mTc-nanocolloid 30 (31) 11 (35)
  Both 52 (53) 18 (58)
 Surgery received, No. (%) .70
  Breast conservation therapy 47 (48) 15 (48)
  Simple mastectomy 50 (51) 15 (48)
  Modified radical mastectomy† 1 (1.0) 1 (3.2)
Abbreviations: ALND, axillary lymph node dissection; SNL, sentinel lymph node; SNLB, sentinel 
lymph node biopsy.
*P value for nominal variables by χ2 test. Continuous variables compared by t test if distributed 
normally and by Wilcoxon rank sum if distribution was skewed.
†All patients who underwent a modified radical mastectomy also underwent an ALND.
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of this technique in HICs, there have been few 
published reports of successful programs from 
Africa. One cohort of 115 patients from Tunisia 
who underwent both an SLNB and an ALND re-
ported an SLN identification rate of 97.3% and a 
false-negative rate of 2.6%.18 However, no data 
have been published from Eastern Africa. To our 
knowledge, our study, from a single center in 
Nairobi, Kenya, is the first to report on the pa-
thology and recurrence of patients who under-
went an SLNB in this region.
In this study of 129 women with stage I and 
II breast cancer who underwent an SLNB in a 
Kenyan hospital between 2008 and 2017, we 
found that 31 (24%) of the 129 patients had a 
positive SLNB, including 10 (14%) of the 73 pa-
tients with stage I disease and 21 (38%) of the 
56 patients with stage II disease. Moreover, one 
or more additional positive lymph nodes were 
found in 21 (91%) of the 23 SLNB-positive pa-
tients who underwent ALND. The overall SLNB 
positivity rate was similar to those of cohorts 
from HICs, which report SLNB positivity rates 
that range from 24.4% to 28.5%.15,19 In addition, 
we described the 2-year locoregional recurrence 
rates after treatment with this procedure.
Overall, the regional recurrence rate for patients 
in our study who were observed for at least 2 
years after surgery was 5.1%. This recurrence 
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Table 2. Pathologic Characteristics by SLNB
Characteristic
Negative SLNB 
(n = 98)
Positive SLNB 
(n = 31) P*
Histology, No. (%)
 Ductal NOS 93 (95) 27 (87) .007
 Lobular NOS 0 (0) 3 (10)
 Other† 5 (5.1) 1 (3.2)
 Lymphovascular invasion 44 (45) 25 (81) .001
 Tumor grade .6
  Grade 1 12 (12) 3 (10)
  Grade 2 48 (49) 12 (39)
  Grade 3 37 (38) 16 (52)
Tumor size, cm, median (range) 2.5 (0.8-10) 3 (1.2-10.5) .5
Immunohistochemistry,‡ No. (%)
 Individual receptors
  Estrogen receptor 78 (82) 24 (77) .6
  Progesterone receptor 75 (79) 23 (74) .6
  HER2 receptor 10 (11) 6 (19) .2
 Receptor combinations
  ER+ and/or PR+ HER2− 71 (75) 20 (65) .3
  ER+ and/or PR+ HER2+ 9 (9.5) 4 (13) .6
  ER− and PR− and HER2+ 1 (1.0) 2 (6.5) .09
  ER− and PR− and HER2− 14 (15) 5 (16) .9
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NOS, 
not otherwise specified; PR, progesterone receptor; SNLB, sentinel lymph node biopsy.
*P value for nominal variables by χ2 test. Continuous variables compared by t test if normally 
distributed and by Wilcoxon rank sum if skewed.
†Other cancer diagnoses included metaplastic carcinoma and invasive mammary carcinoma.
‡n = 95 for negative sentinel lymph node and n = 31 for positive sentinel lymph node.
Included in study
(n = 129)
Underwent SLNB
(N = 138)
Did not undergo
ALND
(n = 95)
Did not undergo
ALND
(n = 8)
Excluded because 
of missing data
(n = 9)
Negative SLNB
(n = 98)
Underwent ALND
(n = 3)
ALND positive
(n = 0)
Positive SLNB
(n = 31)
Underwent ALND
(n = 23)
ALND positive
(n = 21)
Fig. 1. Patients who 
underwent sentinel lymph 
node biopsy (SLNB) 
and axillary lymph node 
dissection (ALND). Patients 
who did not undergo an 
ALND after a positive SLNB 
had two or fewer positive 
sentinel lymph nodes and 
were prescribed whole-
breast radiotherapy and 
breast conservation therapy.  
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rate is significantly better than that of the Na-
tional Surgical Adjuvant Breast and Bowel Proj-
ect B-04 trial, which randomly assigned women 
with nonpalpable axillary lymph nodes to radi-
cal mastectomy, total mastectomy plus regional 
radiotherapy, or simple mastectomy alone and 
showed no survival benefit among the three treat-
ment arms but demonstrated an axillary lymph 
node recurrence rate of 18.6% among women 
treated with total mastectomy alone.20 Although 
our results are preliminary, they suggest that the 
SLNB program at AKUH is successful in identi-
fying women with positive axillary lymph nodes 
and removing them through ALND compared 
with treating them with a total mastectomy alone. 
However, the 2-year recurrence rate is still much 
higher than 0.7% to 2.4% at 2 years and 5.3% 
to 6.2% at 10 years, as reported in the Z0011 
trial, which assessed the need to complete an 
ALND among patients with a positive SLNB and 
found no difference in local recurrence-free sur-
vival between patients who underwent an ALND 
and those who did not. Importantly, however, 
in the Z0011 trial, 96% of patients were treat-
ed with systemic adjuvant therapy and 100% of 
patients received radiotherapy, compared with 
our cohort, in which 60% received systemic ad-
juvant chemotherapy, 85% of eligible women 
received endocrine therapy, and 62% received 
radiotherapy.21 This discrepancy highlights the 
need for AKUH and other cancer centers in the 
region to ensure that patients receive appropri-
ate medical and radiation therapy in addition to 
cancer surgery.
Interestingly, however, all four patients who had 
a recurrence received both adjuvant chemo-
therapy and radiotherapy, suggesting that the 
increased recurrence rates in the AKUH cohort 
may be driven partially by the characteristics of 
the primary tumor. Compared with the Z0011 
trial and others from HICs, the cohort at AKUH 
had more black participants, larger tumors, 
more stage II disease, and greater rates of lym-
phovascular invasion,15,21 which may have led 
to increased relapse rates in the AKUH cohort 
compared with those in HICs. This highlights the 
need for primary cancer management research 
in the region to explain the difference in out-
comes and to determine if the most appropriate 
way to manage early-stage disease in Africa is 
the same as in HICs, or must be modified.
One of the strengths of our study was the com-
pleteness of our database, which included IHC 
for > 97% of participants and had < 3% miss-
ing values for any included variable. Another 
strength was the availability of follow-up data for 
2 years after surgery on > 60% of our cohort, 
which allowed us to document the incidence of 
early recurrence after SLNB and ALND. 
The limitations of our study include its small 
sample size, the retrospective study design, and 
our primary reliance on two highly skilled sur-
geons, which limits the generalizability of our re-
sults to all centers within the region. In addition, 
we did not systematically collect data on com-
mon complications of SLNB and ALND, such as 
lymphedema and axillary numbness, which pre-
vented us from being able to assess the impact 
of SLNB on these important causes of morbidity.
In conclusion, to our knowledge, our study de-
scribes for the first time the clinical and patho-
logic characteristics and early recurrence expe-
rience of patients with stage I and stage II breast 
cancer who underwent an SLNB in East Africa. 
This study shows that although some tumor 
characteristics are similar between our cohort 
and cohorts from HICs, early recurrence rates 
seem to be higher at AKUH. To explain this dis-
crepancy in recurrence rates, more primary data 
on the treatment of early breast cancer in Africa 
are needed.
DOI: https://doi.org/10.1200/JGO.17.00111 
Published online on jgo.org on December 7, 2017.
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Table 3. Clinical Characteristics of Those With Regional Recurrence Among the 79 Patients Observed for > 2 Years
Patient
Age at Diagno-
sis (years) Positive SLNB ER Receptor PR Receptor HER Receptor
Years After 
Initial Surgery
1 48 No Negative Negative Negative 1.2
2 49 No Positive Positive Negative 2.7
3 31 Yes Negative Negative Negative 1.0
4 58 Yes Positive Positive Negative 5.7
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SNLB, sentinel 
lymph node biopsy.
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